Orlistat in hypertensive overweight/obese patients: results of a randomized clinical trial

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Hypertension

• Publication date

  2003-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00004872-200311000-00026PMID 14597860
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Orlistat

  2012cited by this paper
• Randomized controlled trials.

  2004cited by this paper
• The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo‐controlled trial

  2002cited by this paper
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

  2002cited by this paper
• The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes.

  2002cited by this paper
• A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients.

  2002cited by this paper
• Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension

  2002cited by this paper
• Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension

  2002cited by this paper
• The CONSORT Statement: Revised Recommendations for Improving the Quality of Reports of Parallel-Group Randomized Trials

  2001cited by this paper
• Sympathetic nervous system and insulin resistance: from obesity to diabetes.

  2001cited by this paper
• The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study

  2001cited by this paper
• The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials

  2001cited by this paper
• Weight reduction and pharmacologic treatment in obese hypertensives.

  2001cited by this paper
• A rapid and systematic review of the clinical effectiveness and cost-effectiveness of debriding agents in treating surgical wounds healing by secondary intention.

  2001cited by this paper
• Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X.

  2001cited by this paper
• The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

  2001cited by this paper
• A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity.

  2001cited by this paper
• Subgroup analysis and other (mis)uses of baseline data in clinical trials.

  2000cited by this paper
• The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study

  2000cited by this paper
• [Years of life lost by mortality: a component of the burden of disease].

  1999cited by this paper
• Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.

  1999cited by this paper
• Report of the expert committee on the diagnosis and classification of diabetes mellitus.

  1999cited by this paper
• Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.

  1999cited by this paper
• What is meant by intention to treat analysis? Survey of published randomised controlled trials

  1999cited by this paper
• Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.

  1998cited by this paper
• Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients

  1998cited by this paper
• Attitudes in clinical trials.

  1998cited by this paper
• Role of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes: A 1-year randomized double-blind study

  1998cited by this paper
• Treatment with orlistat reduces cardiovascular risk in obese patients

  1998cited by this paper
• The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.

  1997cited by this paper
• Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

  1997cited by this paper
• Resistant hypertension: an overview.

  1996cited by this paper
• High temporal, geographic, and income variation in body mass index among adults in Brazil.

  1994cited by this paper
• [Arterial hypertension and obesity in Ilha do Governador-Rio de Janeiro].

  1994cited by this paper
• Hipertensão Arterial e Obesidade na Ilha do Governador - Rio de Janeiro

  1994cited by this paper
• Is obesity-related hypertension less of a cardiovascular risk? The Framingham Study.

  1990cited by this paper
• Explanatory and pragmatic attitudes in therapeutical trials.

  1967cited by this paper

• A systematic review, ANCOVA meta-analysis, and meta-regression of clinical trials: Orlistat and body mass index of overweight and obese patients

  2024cites this paper
• Orlistat, a competitive lipase inhibitor used as an antiobesity remedy, enhances inflammatory reactions in the intestine

  2022cites this paper
• The comparison of treatment with orlistat and orlistat plus metformin in relation to insulin resistance and weight loss

  2022cites this paper
• The clinical efficacy of orlistat in the treatment of obesity

  2020cites this paper
• Cardioprotective effect of lipstatin derivative orlistat on normotensive rats submitted to cardiac ischemia and reperfusion.

  2018cites this paper
• Effects of orlistat on blood pressure: a systematic review and meta-analysis of 27 randomized controlled clinical trials.

  2017cites this paper
• Effect of orlistat on plasma lipids and body weight: A systematic review and meta‐analysis of 33 randomized controlled trials

  2017cites this paper
• Beneficial effects of training at the anaerobic threshold in addition to pharmacotherapy on weight loss, body composition, and exercise performance in women with obesity

  2015cites this paper
• IQP-GC-101 Reduces Body Weight and Body Fat Mass: A Randomized, Double-Blind, Placebo-Controlled Study

  2014cites this paper
• Macrocytic Anemia and Thrombocytopenia Induced by Orlistat

  2013cites this paper
• Dissertação apresentada com vistas à obtenção do título de Mestre em Ciências, na área de Epidemiologia em Saúde Pública.

  2012cites this paper
• What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.

  2012cites this paper
• Orlistat

  2012cites this paper
• Fatores de risco cardiovascular entre docentes de uma Universidade Pública de Minas Gerais

  2010cites this paper
• Comparative study of the pro-atherosclerotic profile of students of medicine and physical education.

  2010cites this paper
• Estudo Comparativo do Perfil Pró-Aterosclerótico de Estudantes de Medicina e de Educação Física Comparative Study of the Pro-Atherosclerotic Profile of Students of Medicine and Physical Education

  2010cites this paper
• Estudio comparativo del perfil pro-aterosclerótico de estudiantes de medicina y de educación física

  2010cites this paper
• Obez hastalarda kısa dönem (1 aylık) orlistat tedavisinin plazma lipid düzeylerine etkisi

  2009cites this paper
• Trends in hypertension treatment in diabetes

  2009cites this paper
• Obesity Management Interventions: A Review of the Evidence

  2009cites this paper
• Orlistat-Associated Adverse Effects and Drug Interactions

  2008cites this paper
• Acute effects of orlistat on postprandial serum leptin levels in nondiabetic obese patients.

  2008cites this paper
• State of the Art Review: Long-term Pharmacotherapy for Overweight and Obesity: A Review of Sibutramine, Orlistat, and Rimonabant

  2007cites this paper
• Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.

  2006cites this paper
• Body mass index and waist circumference: association with cardiovascular risk factors.

  2006cites this paper
• Body mass index and waist circumference: association with cardiovascular risk factors.

  2006cites this paper
• Spotlight on Orlistat in the Management of Patients with Obesity

  2005cites this paper
• Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus.

  2005cites this paper
• Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials 1,2

  2004cites this paper
• Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials.

  2004cites this paper